Auvi-Q (Kaléo; previously manufactured and marketed by Sanofi), the epinephrine auto-injector approved by the FDA in 2012 for emergency treatment of anaphylaxis and voluntarily withdrawn in 2015 due to potential inaccurate dosage delivery,1 has become available once more. According to Kaléo, improvements in the manufacturing process have addressed the concerns that led to its recall.
THE DEVICE — No changes were made to the device itself, which is about the length and width of a credit card and as thick as a smartphone. It has an automatic needle retraction system and a red safety guard at the needle-end of the device. Removal of the outer case initiates visual signals and an audio recording that provides step-by-step instructions and a 5-second countdown during the injection process. The shelf-life of the epinephrine in the auto-injector is 18 months; the shelf-life of the battery is longer....
- Crisaborole (Eucrisa) for Atopic Dermatitis
- Anticoagulation of Elderly Patients at High Risk for Falls with Atrial Fibrillation
- Extended-Release Calcifediol (Rayaldee) for Secondary Hyperparathyroidism
- Kyleena - Another Hormonal IUD
- Drug Interaction: Clopidogrel and PPIs
- Atezolizumab (Tecentriq) for Bladder Cancer and NSCLC (online only)
- Drugs for Migraine
- Comparison Chart of Triptans (online only)
- Comparison Chart of Drugs for Migraine Prevention (online only)
The FDA has approved crisaborole 2% ointment (Eucrisa – Pfizer) for topical treatment of mild to moderate atopic dermatitis in patients ≥2 years old. It is the first phosphodiesterase type-4 (PDE4) inhibitor to be approved in the US for this indication.
ATOPIC DERMATITIS — Atopic dermatitis (also known as atopic eczema) is a chronic pruritic inflammatory skin disease that commonly presents in infancy or early childhood and is frequently associated with other atopic disorders such as allergic rhinitis and asthma. It has a relapsing course, often ...